Coagulation factor content of plasma produced from whole blood stored for 24 hours at ambient temperature: results from an international multicenter BEST Collaborative study
R. Cardigan
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorP.F. Van der Meer
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorC. Pergande
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorP. Cookson
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorB. Baumann-Baretti
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorJ.A. Cancelas
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorD. Devine
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorH. Gulliksson
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorR. Vassallo
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorJ. de Wildt-Eggen
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorR. Cardigan
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorP.F. Van der Meer
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorC. Pergande
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorP. Cookson
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorB. Baumann-Baretti
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorJ.A. Cancelas
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorD. Devine
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorH. Gulliksson
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorR. Vassallo
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorJ. de Wildt-Eggen
From the NHS Blood and Transplant, Brentwood, UK; the Sanquin Blood Bank North West Region, Amsterdam, the Netherlands; Haema AG, Berlin, Germany; the Hoxworth Blood Center and Division of Experimental Hematology, Cincinnati, Ohio; the Canadian Blood Service, Vancouver, British Columbia, Canada; the Karolinska University Hospital, Stockholm, Sweden; the American Red Cross Blood Services, Philadelphia, Pennsylvania; and the Sanquin Blood Bank, Groningen, the Netherlands.
Search for more papers by this authorAbstract
BACKGROUND: There is increasing international interest in producing components from blood that has been stored at room temperature for 24 hours. The lack of comprehensive data on the quality of plasma produced from blood stored in this way led to this international study.
STUDY DESIGN AND METHODS: A total of 128 units of whole blood were pooled in groups of four and split to produce 32 sets of four identical blood units that were processed either within 8 hours of blood collection or after 24-hour storage at 18 to 25°C.
RESULTS: Storage of whole blood for 24 hours resulted in a 23% decrease in the activity of Factor (F)VIII, but not significant loss of activity of coagulation factors FV, FVII, FXI, FXII, fibrinogen, antithrombin, or von Willebrand factor. There was a small, but significant decrease in levels of FII, FIX, and FX (all <5%) as well as protein C (6%) and free protein S activity (14%). The ability of plasma to generate thrombin after 24-hour storage as whole blood was unaltered, as assessed by real-time thrombin generation tests as was the rate and strength of clot formation by rotational thombelastometry. Levels of all coagulation factors measured were above 0.50 U/mL in plasma produced from whole blood stored for 24 hours.
CONCLUSION: These data show that there is minimal effect of storing whole blood at ambient temperature for 24 hours on the coagulation activity of plasma and that this is an acceptable alternative to producing plasma on the day of blood collection.
REFERENCES
- 1 Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, Navarrete C, Lucas G, Soni N, Morgan C, Choo L, Cohen H, Williamson LM, Serious Hazards of Transfusion Steering Group. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009; 49: 440-52.
- 2 AABB Standards Program Committee. Standards for blood banks and transfusion services. 26th ed. Bethesda: AABB; 2009.
- 3 Cardigan R, Lawrie AS, Mackie IJ, Williamson LM. The quality of fresh-frozen plasma produced from whole blood stored at 4 degrees C overnight. Transfusion 2005; 45: 1342-8.
- 4 Guide to the preparation, use and quality assurance of blood components. 14th ed. Strasbourg: Council of Europe Publishing; 2009.
- 5 Guidelines for the blood transfusion services in the United Kingdom. 7th ed. London: The Stationary Office; 2005.
- 6 O'Neill EM, Rowley J, Hansson-Wicher M, McCarter S, Ragno G, Valeri CR. Effect of 24-hour whole-blood storage on plasma clotting factors. Transfusion 1999; 39: 488-91.
- 7 Smith JF, Ness PM, Moroff G, Luban NL. Retention of coagulation factors in plasma frozen after extended holding at 1-6 degrees C. Vox Sang 2000; 78: 28-30.
- 8 Katz LM, Kiss JE. Plasma for transfusion in the era of transfusion-related acute lung injury mitigation. Transfusion 2008; 48: 393-7.
- 9 Scott E, Puca K, Heraly J, Gottschall J, Friedman K. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6 degrees C storage. Transfusion 2009; 49: 1584-91.
- 10 Pietersz RN, de Korte D, Reesink HW, Dekker WJ, van den Ende A, Loos JA. Storage of whole blood for up to 24 hours at ambient temperature prior to component preparation. Vox Sang 1989; 56: 145-50.
- 11 McLaughlin LS, Moroff G, Benjamin RJ. Facilitating blood component preparation: the impact of overnight room temperature storage. Transfusion 2010; 50: 278-80.
- 12 Chabanel A, Sensebe I, Masse M, Maurel JP, Plante J, Hivet D, Kannengiesser C, Naegelen C, Joussemet M, Marchesseau B, Rasongles P, Proust F, David C, Montembault AM, Bergeat P. Quality assessment of seven types of fresh-frozen plasma leucoreduced by specific plasma filtration. Vox Sang 2003; 84: 308-17.
- 13 Kretzschmar E, Kruse F, Greiss O, Paunovic D, Kallweit T, Trobisch H. Effects of extended storage of whole blood before leucocyte depletion on coagulation factors in plasma. Vox Sang 2004; 87: 156-64.
- 14 Heiden M, Salge U, Henschler R, Pfeiffer HU, Volkers P, Hesse J, Sireis W, Seitz R. Plasma quality after whole-blood filtration depends on storage temperature and filter type. Transfus Med 2004; 14: 297-304.
- 15 Hemker HC, Giesen P, al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Béguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
- 16 Allersma DP, Imambaks RM, Meerhof LJ. Effect of whole blood storage on factor VIII recovery in fresh frozen plasma and cryoprecipitate. Vox Sang 1996; 71: 150-4.
- 17 Hughes C, Thomas KB, Schiff P, Herrington RW, Polacsek EE, McGrath KM. Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate. Transfusion 1988; 28: 566-70.
- 18 Pepper MD, Learoyd PA, Rajah SM. Plasma factor VIII, variables affecting stability under standard blood bank conditions and correlation with recovery in concentrates. Transfusion 1978; 18: 756-60.
- 19 Nilsson L, Hedner U, Nilsson IM, Robertson B. Shelf-life of bank blood and stored plasma with special reference to coagulation factors. Transfusion 1983; 23: 377-81.
- 20 Weisert O, Jeremic M. Preservation of coagulation factors V and VIII during collection and subsequent storage of bank blood in ACD-A and CPD solutions. Vox Sang 1973; 24: 126-33.
- 21 O'Shaughnessy DF, Atterbury C, Bolton MP, Murphy M, Thomas D, Yates S, Williamson LM, British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 11-28.
- 22 Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 2004; 14: 39-44.
- 23 Scott EA, Puca KE, Pietz BC, Duchateau BK, Friedman KD. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion 2007; 47: 120-5.
- 24 de la RJ, Arriaga F, Linares D, Larrea L, Carpio N, Marty ML, Sanz MA. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001; 114: 721-3.
- 25 Rio-Garma J, Alvarez-Larran A, Martinez C, Muncunill J, Castellà D, de la Rubia J, Zamora C, Corral M, Viejo A, Peña F, Rodríguez-Vicente P, Contreras E, Arbona C, Ramírez C, Garcia-Erce JA, Alegre A, Mateo J, Pereira A. Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008; 143: 39-45.
- 26 Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003; 121: 778-85.
- 27 Downes KA, Wilson E, Yomtovian R, Sarode R. Serial measurement of clotting factors in thawed plasma stored for 5 days. Transfusion 2001; 41: 570.
- 28 Nifong TP, Light J, Wenk RE. Coagulant stability and sterility of thawed S/d-treated plasma. Transfusion 2002; 42: 1581-4.
- 29 Yazer MH, Cortese-Hassett A, Triulzi DJ. Coagulation factor levels in plasma frozen within 24 hours of phlebotomy over 5 days of storage at 1 to 6 degrees C. Transfusion 2008; 48: 2525-30.
- 30 Wilsher CK, Garwood M, Sutherland J, Turner C, Cardigan R. The effect of storing whole blood at 22°C for up to 24 hours with and without rapid cooling on the quality of red cell concentrates and fresh frozen plasma. Transfusion 2008; 48: 2338-47.
- 31 Serrano K, Scammell K, Weiss S, Culibrk B, Levin E, Gyöngyössy-Issa M, Devine DV. Plasma and cryoprecipitate manufactured from whole blood held overnight at room temperature meet quality standards. Transfusion 2010; 50: 344-53.
- 32 Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DB, Murphy MF. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004; 126: 139-52.
